¹ The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

COBENFY™ (xanomeline and trospium chloride) is indicated for the treatment of schizophrenia in adults. For Important Safety Information, see U.S. Full Prescribing Information, including Patient Information on COBENFY.com.
Note: PureTech retains control of Entrega, Inc. and Seaport Therapeutics, and they are consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc.
¹ Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of June 30, 2024, and Seaport as of October 18, 2024, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Gallop Oncology, Inc. Vor Biopharma ownership was calculated on a beneficial ownership basis in accordance with SEC rules as of March 13, 2025. ² As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

$400.6M

PureTech Level Cash, Cash Equivalents and Short-Term Investments
as of June 30, 2024³

³ PureTech Level Cash, cash equivalents and short-term investments is a Non-IFRS measure.